Withdrawals due to adverse events · Patients with active Crohn's disease
Budesonide 9 mg showed no clear difference in withdrawal due to adverse events compared with conventional steroids (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Budesonide 3 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Budesonide 9 mg showed no clear difference in withdrawal due to adverse events compared with mesalamine (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Budesonide 9 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events ‐ recurrent fever · acute bacterial meningitis
The intervention probably leads to higher adverse events ‐ recurrent fever (moderate certainty).
1 finding from 1 review
Number of serious adverse events · patients with osteoarthritis
Chondroitin probably leads to lower number of serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · Adult patients with active ulcerative colitis
Budesonide MMX® 6 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Adult patients with active ulcerative colitis
Budesonide MMX® 9 mg showed no clear difference in withdrawal due to adverse events compared with entocort EC 9mg (moderate certainty).
1 finding from 1 review
All‐cause serious adverse events · chronic obstructive pulmonary disease (COPD). Participants in included studies had an average baseline FEV1 of around 40% predicted and…
Tiotropium leads to lower all‐cause serious adverse events compared with ipratropium (high certainty).
1 finding from 1 review
Intervention not reported
Adverse events: hypersensitivity · People with AML in first complete remission
It is very uncertain whether the intervention changes adverse events: hypersensitivity (very low certainty).
1 finding from 1 review
Treatment‐related adverse events · non‐allergic rhinitis
The review found no eligible studies for this question.
1 finding from 1 review
Treatment‐related adverse events · patients with non‐allergic rhinitis
The review found no eligible studies for this question.
1 finding from 1 review
Treatment‐related adverse events · patients with non‐allergic rhinitis
The review found no eligible studies for this question.
1 finding from 1 review
Number of serious adverse events · patients with axSpA (AS and nr‐axSpA)
COX‐2 NSAIDs showed no clear difference in number of serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.92 [0.14, 6.21]
669 participants
Moderate
Number of serious adverse events · patients with axSpA (AS and nr‐axSpA)
Traditional NSAIDs showed no clear difference in number of serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
RR 1.69 [0.36, 7.97]
671 participants
Moderate
Wound infection · people with pressure ulcers
Hydrogel dressings showed no clear difference in adverse events (wound infection) compared with hydrogel dressings (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with osteoarthritis
Diacerein showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Gastrointestinal adverse events · women with polycystic ovary syndrome
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Serious adverse events(12 months) · children and young people with JIA
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Withdrawals due to adverse events · postmenopausal women with a higher risk for fracturesa
It is very uncertain whether intermittent/cyclic etidronate 400 mg/day changes withdrawals due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
RR 1.09 [0.54, 2.18]
Studies not reported
Very low